Q-omics provides the consensus-scored FTLP16 profile across patient tissues and cancer cell-line models. FTLP16 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, FTLP16 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, FTLP16 RNA expression shows 6,175 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and THCA as cancer lineages where FTLP16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FTLP16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FTLP16 survival associations across molecular data types. FTLP16 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FTLP16 RNA expression–survival associations across cancer types. High FTLP16 expression shows unfavorable associations in STAD, UCEC, UCS, ACC and LIHC, but favorable associations in HNSC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for FTLP16 RNA expression.
This table summarizes FTLP16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FTLP16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FTLP16 shows lower tumor expression in THCA and higher tumor expression in COAD and LUSC. The THCA box plot shows higher FTLP16 RNA expression in normal versus tumor tissue (log2 FC = −0.418, t-test p < 0.001).
This table shows molecular features associated with FTLP16 in patient tissues and cancer cell lines. In patient samples, FTLP16 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
